#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Sports in People with Hemophilia –⁠ Possible and Safe

Active involvement in sports and an active lifestyle are important aspects of daily functioning for people with hemophilia. Modern treatment of this disease, including the prophylactic administration of concentrates of the missing coagulation factor, has led to an increase in the number of very active patients. Numerous studies have confirmed that they are as physically active as the general population, although some emphasize that this is more relevant to children and young people. Therefore, the work of Dutch and Swedish authors focused on examining the relationship between age and physical activity in hemophiliacs, especially with regard to more intensive and riskier sports.
Source: Hemophilia with Movement 19. 6. 2023

Journal articles A severe course of acquired haemophilia A –⁠ case report

Author of the article: M. Chobola, V. Šrámek, J. Hruda Source: Anesteziologie a intenzivní medicína | 2/2012 30. 5. 2012

News Impact of Comorbidities on the Efficacy of Ceftaroline Fosamil in Complicated Skin and Soft Tissue Infections −⁠ Pooled Analysis of 3 Studies

In 3 randomized Phase III studies, ceftaroline fosamil demonstrated non-inferiority in treating complicated skin and soft tissue infections (cSSTI) compared to vancomycin + aztreonam. A recent pooled analysis of these 3 studies evaluated the impact of age and comorbidities on clinical outcomes.
Source: Anti-Infectives 17. 3. 2023

News Experience from Clinical Practice with Intestinal Gel LECIG in Treating Parkinson's Disease

A Swedish observational study evaluated the applicability of the LECIG intestinal gel, which contains levodopa (20 mg/ml), carbidopa (5 mg/ml), and entacapone (20 mg/ml), in clinical practice for patients with Parkinson's disease.
Source: Parkinson's Disease 12. 5. 2022

News Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention

Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk due to its proven mortality reduction. However, many patients with familial hypercholesterolemia or CV disease fail to reach target LDL-c levels even when given the maximum tolerated dose of conventional hypolipidemic treatment. For these patients, inclisiran—a small interfering RNA (siRNA) that lowers cholesterol—offers hope. In the following article, we present a model example of a patient after an acute coronary event for whom starting inclisiran treatment is appropriate.
Source: Chronic Heart Failure and Lipidology 23. 12. 2022

News Do Beta-Blockers Increase the Risk of Hypoglycemia in Patients with Diabetes and Atherosclerosis?

Given that a large portion of patients with diabetes have proven cardiovascular disease, several clinical studies or their subsequent analyses address the effects of beta-blockers in these patients. One such analysis was the post-hoc analysis of the TECOS study, which among other things, attempted to evaluate the connection between the use of beta-blockers in type 2 diabetics with proven atherosclerotic cardiovascular disease and the incidence of hypoglycemic episodes.
Source: Cardiovascular Continuum 18. 5. 2020

News Turoctocog Alfa in Tertiary Prophylaxis of Hemophilia A or Is It Always About Bleeding? Case Studies

This case report from our own practice concerns our experience with the treatment of hemophilia A with turoctocog alfa. The intention is, among other things, to compare different outcomes in our two patients regarding their self-assessment of bleeding without objective validation.
Source: Hemophilia with Movement 19. 8. 2022

Journal articles Case history acquired haemophilia A

Author of the article: Z. Čermáková, R. Hrdličková, Š. Blahutová, A. Ligová Source: Vnitřní lékařství | 4/2013 1. 4. 2013

News Brief from ASH 2021: News and Advances in CLL Treatment

The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in Atlanta in December 2021 brought several new advancements in the treatment of chronic lymphocytic leukemia (CLL). Dr. Brian Koffman from the CLL Society provided commentary on these developments.
Source: Chronic Lymphocytic Leukemia 12. 4. 2022

News Ixekizumab administered for 5 years demonstrated high efficacy and a favorable safety profile in patients with moderate to severe psoriasis

Ixekizumab is a recombinant humanized monoclonal antibody against interleukin 17A, indicated for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. At the 24th World Congress of Dermatology in Milan in June 2019, results were presented from a study evaluating the efficacy and safety of long-term administration of ixekizumab.
Source: Biological Treatment 19. 5. 2020

Journal articles Why do we still hesitate to accept the new international criteria for the diagnosis of gestational diabetes mellitus?
The current screening is non-uniform and does not correspondwith evidence-based medicine

Author of the article: H. Krejčí, K. Anderlová Source: Česká gynekologie | 3/2014 18. 6. 2014

News Effectiveness of Dietary Intervention in Irritable Bowel Syndrome –⁠ Results of a Network Meta-Analysis

A low FODMAP diet is often recommended to alleviate symptoms of irritable bowel syndrome (IBS). Although several randomized studies have been conducted to assess the effectiveness of this diet, a systematic evaluation has yet to be available, and individual studies have used various control interventions. Therefore, an international team of researchers decided to prepare a systematic literature review with a network analysis, recently published in the journal Gut.
Source: Irritable Bowel Syndrome 12. 10. 2022

News Safety of Urgent Initiation of Peritoneal Dialysis

In case of urgent need for kidney function replacement, hemodialysis (HD) with a temporary venous catheter has long been the standard solution. However, it has several disadvantages such as increased mortality or the risk of bacteremia and central venous stenosis. Additionally, multiple procedures are needed to create a permanent venous access. Therefore, there is a growing global interest in urgently initiated peritoneal dialysis (PD), with several clinical studies attesting to its safety, efficacy, and feasibility. However, little has been known about early PD complications and the long-term prognosis of patients in terms of technical and infectious complications.
Source: Chronic Kidney Disease 8. 6. 2021

News Dupilumab in the Treatment of Adolescent Patients with Severe and Refractory Atopic Dermatitis

An open multicenter study evaluating dupilumab in the treatment of moderate to severe atopic dermatitis in adolescents confirmed its long-term efficacy and safety in this age group. In addition to its results, we also summarize information on dosing and reimbursement conditions in the Czech Republic for the age group 12-18 years.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 1. 12. 2020

News Safety of Riociguat in the Treatment of Thromboembolic Pulmonary Hypertension in Common Practice

In March 2021, the final safety results of riociguat in the treatment of thromboembolic pulmonary arterial hypertension in real-world practice were published from the international EXPERT registry, which also included Czech patients. The safety profile of the therapy was consistent with the findings of previous clinical studies.
Source: Pulmonary hypertension (CTEPH, PAH) 16. 5. 2021

News Pain Relief and Functional Score Improvement in Patients with Low Rheumatoid Arthritis Activity: Baricitinib vs. Adalimumab

In patients with rheumatoid arthritis, pain and functional impairment may persist even with good disease activity control. An exploratory analysis of the RA-BEAM study compared the effects of baricitinib, adalimumab, and placebo added to methotrexate on residual pain and functional scores in patients with rheumatoid arthritis (RA) who achieved remission or low disease activity with this treatment.
Source: Biological Treatment 20. 2. 2020

News Efficacy of Combination Therapy for Chronic Lymphocytic Leukemia in Patients with Complex Karyotype

A complex karyotype (presence of ≥ 3 chromosomal abnormalities) is a negative prognostic marker in chronic lymphocytic leukemia (CLL). An analysis of the impact of complex karyotype on the efficacy of targeted CLL therapy combining the monoclonal antibody against CD20 antigen obinutuzumab with the BCL2 inhibitor venetoclax or the alkylating cytostatic chlorambucil was published in the journal Blood.
Source: Chronic Lymphocytic Leukemia 22. 4. 2020

News Development and Benefits of Intestinal Gel LECIG for Patients with Parkinson's Disease

Patients with advanced Parkinson's disease, for whom the current regimen of orally and transdermally administered medications is insufficient for symptom relief, now have a new treatment option. It involves the continuous administration of an intestinal gel that combines three effective antiparkinsonian drugs.
Source: Parkinson's Disease 10. 3. 2023

News Longer survival without liver transplant in patients with PBC treated with OCA?

Obeticholic acid (OCA) is a second-line treatment for patients with primary biliary cholangitis (PBC) who have an inadequate response to ursodeoxycholic acid (UDCA) or intolerance to it. The study presented below, the results of which were recently published, examined the effectiveness of OCA in reducing cholestatic enzymes as well as the length of survival without liver transplant in patients with PBC.
Source: Primary Biliary Cholangitis 20. 3. 2023

News Alzheimer's Disease –⁠ Another Pandemic on the Horizon?

Due to the COVID-19 pandemic, other current problems often get pushed into the background. One of these is the aging population and the increasing prevalence of dementia. The key question thus becomes how to extend the period of active aging as much as possible.
Source: Cognitive in the treatment of Alzheimer's disease 11. 2. 2022

News Adequate Anti-Xa Levels Are More Often Achieved in Trauma Patients When Dosing Enoxaparin Based on Weight

Thromboembolic disease (TED) is a well-known preventable cause of morbidity and mortality in trauma patients. To improve their prognosis, pharmacological thromboprophylaxis, such as with low molecular weight heparins (LMWH), is an essential part of treatment. However, previously published studies have pointed out that standard dosing of LMWH may be associated with insufficient levels of activity measured using the anti-Xa parameter.
Source: Thromboprophylaxis 3. 3. 2022

News Biosimilar Drugs in Oncology

8 of the 10 most expensive drugs on the market are used in the treatment of cancer. Rising healthcare costs in recent decades have created a need to find strategies to limit these costs. Biosimilar preparations have the potential to partially replace existing original biological drugs and reduce the cost of cancer treatment. We therefore briefly summarize the basic information on the issue of biosimilars in terms of their benefits, safety, and interchangeability.
Source: Oncological Treatment 22. 11. 2021

News Risk of Developing Inhibitors in People with Milder Forms of Hemophilia

Moderate and mild hemophilia A differ from the severe form not only in clinical course and bleeding risk, but also in the risk of developing neutralizing antibodies (inhibitors).
Source: Hemophilia 1. 11. 2021

News Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment

With the development of new treatment options for hemophilia, there has also been progress in methods for monitoring hemophilic arthropathy and identifying it in its early stages. In addition to classical X-rays, clinical scoring systems, and the gold standard of magnetic resonance imaging (MRI), the so-called POCUS –⁠ point-of-care ultrasound –⁠ has emerged as a quick and reliable method for assessing joint health. Potential biomarkers for osteochondral damage and synovial proliferation specific to hemophilia or for detecting joint bleeding are also being investigated, though their routine use is not anticipated in the near future.
Source: Hemophilia 10. 6. 2024

News Intestinal Gel LECIG in the Treatment of Advanced Parkinson's Disease in Real Practice

A recently published study presents the first experiences with an intestinal gel containing a triple combination of antiparkinsonian drugs and dosed via an infusion pump through percutaneous endoscopic gastrostomy extended into the jejunum in the treatment of advanced Parkinson's disease.
Source: Parkinson's Disease 10. 3. 2023

1 11 12 13 14 15 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#